Key Highlights
- Loss per share was USD 0.11 against an estimate of a USD 0.20 loss.
- Net loss was USD 12.11 million, against USD 14.44 million a year earlier.
- Total operating expenses were USD 20.54 million, against USD 14.69 million.
- Cash and marketable securities were USD 201.5 million at September 30.
Achieve Life Sciences (NASDAQ:QUIT) reported a third quarter 2026 loss per share of USD 0.11, against an estimate of a USD 0.20 loss. Net loss was USD 12.11 million, compared with USD 14.44 million in the third quarter of 2025.
Total operating expenses were USD 20.54 million, compared with USD 14.69 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Operating Expenses
Research and development expenses were USD 5.36 million, compared with USD 5.32 million, and Research and Development expenses from related parties were USD 857 thousand. The filing attributes the increase primarily to USD 1.9 million of higher Manufacturing and Supply chain costs, associated with manufacturing development, including the purchase of raw cytisinicline inventory and finished drug product, and USD 0.7 million of higher employee expenses tied to severance and increased headcount. These were partially offset by a USD 1.8 million decrease in clinical trial costs associated with the ORCA-OL trial, which was completed in October 2025.
General and administrative expenses were USD 14.32 million, compared with USD 9.37 million. Interest income was USD 1.79 million, compared with USD 554 thousand, and interest expense was USD 258 thousand, compared with USD 192 thousand. For the nine months, interest income was USD 3.56 million, against USD 1.07 million, and interest expense was USD 809 thousand, against USD 568 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, net loss was USD 97.05 million, compared with USD 39.99 million. The Cash Flow Statement reflects an adjustment of USD 41.6 million for the change in Fair Value of the Warrant liability. Total operating expenses for the nine months were USD 49.39 million, against USD 40.15 million, and general and administrative expenses were USD 36.03 million, against USD 21.03 million.
Liquidity and Capital Structure
As of September 30, 2026, the company had an accumulated Deficit of USD 357.3 million, cash, cash equivalents and marketable securities of USD 201.5 million, and positive Working Capital of USD 184.0 million.
On July 2, 2026, stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The filing also describes a New Debt Agreement and a Registration Rights Agreement with the lender covering shares issuable upon conversion of outstanding debt.
The June 2025 public offering of 15,000,000 shares and 15,000,000 accompanying warrants raised total gross proceeds of approximately USD 45.0 million, and net proceeds of approximately USD 41.2 million after approximately USD 3.8 million of Underwriting discounts and offering expenses.
Achieve Life Sciences Q3 2026 Earnings: Key Takeaways
Achieve Life Sciences reported a third quarter 2026 loss per share of USD 0.11 and a net loss of USD 12.11 million. Total operating expenses were USD 20.54 million, and cash, cash equivalents and marketable securities were USD 201.5 million.






Please wait processing your request...